PET imaging agent Pylarify accurately detects prostate cancer
- Vitamin D supplementation may help strengthen Long-COVID recovery
- What bacteria and viruses can cause cancers?
- The world first TIL cell therapy targeting advanced melanoma is coming soon
- The Pros and Cons of Radiotherapy Affecting Antitumor Immunity
- Oral probiotics can enhance the effects of immunotherapy
- Genetic study reveals why one Scottish woman can’t feel pain and her wounds heal faster
PET imaging agent Pylarify was launched, accurately detecting the recurrence and metastasis of prostate cancer
PET imaging agent Pylarify accurately detects prostate cancer. Prostate cancer that is diagnosed at an advanced stage, how to find it early?
Recently, the US FDA approved the listing of Pylarify (Piflufolastat F18), a positron emission tomography (PET) imaging agent, to identify suspected recurrent/metastatic prostate cancer.
Pylarify is the first and only commercially available PET imaging agent that targets prostate-specific membrane antigen (PSMA). Compared with traditional imaging tests, it can help doctors find suspected recurrence/metastasis earlier and more accurately Prostate cancer, so as to develop a better treatment plan.
▌Diagnosis means advanced prostate cancer, how to find it early?
Prostate cancer is the second most common type of cancer among men. According to WHO estimates, there are approximately 1.3 million newly diagnosed cases worldwide and approximately 400,000 deaths per year.
Prostate cancer is not obvious because of its early symptoms, and it is easy for patients to ignore it. About half of the patients are already at an advanced stage when they are diagnosed. With the improvement of the level of screening, more and more prostate cancer patients have been discovered through digital rectal examination, prostate-specific antigen (PSA) testing, ultrasound, needle biopsy, etc.
In addition, CT, MRI scans, and bone scans can also be used to check for prostate cancer, but these methods have limitations in detecting prostate cancer lesions.
In early December last year, the radiological diagnostic agent Ga 68 PSMA-11 was approved for the market, which can be used for PET imaging of PSMA-positive lesions for patients with suspected prostate cancer metastasis, becoming the first PET imaging agent targeting PSMA.
▌PET developer: Pylarify
Among male patients with localized prostate cancer receiving initial radical treatment, up to 50% of patients may experience disease recurrence within 10 years after treatment.
Recurrent disease is usually detected by elevated serum prostate-specific antigen (PSA) levels. However, conventional imaging examinations have certain limitations. Especially at low PSA levels, in most cases the location and extent of the disease cannot be determined, and early spread to distant organs such as lymph nodes, bones and other organs cannot be well detected.
Pylarify is a radioactive fluorinated small molecule imaging agent targeting prostate specific membrane antigen (PSMA). PSMA is a protein that is overexpressed on the surface of more than 90% of primary and metastatic prostate cancer cells. It can show lymph node, bone and soft tissue metastasis to determine whether prostate cancer has recurred and/or metastasized.
Pylarify PET combines the accuracy of PET imaging, the accuracy of PSMA targeting and the clarity of the F18 radioisotope, as if it has a “fire eye”, with more accurate diagnostic performance.
Pylarify injection indications:
- Suspected metastases, preliminary determination of the treatment plan;
- Patients suspected of relapse based on elevated serum prostate-specific antigen (PSA) levels.
▌Innovative PET imaging agent, early and accurate detection of cancer recurrence and metastasis!
The approval of Pylarify is based on positive data from two key studies (OSPREY and CONDOR), which enrolled a total of 593 patients to determine the safety and diagnostic performance of Pylarify in prostate cancer patients.
The results of the OSPREY study show:
Compared with traditional imaging, Pylarify PET imaging has improved specificity and positive predictive value (PPV) before initial treatment for patients with metastatic prostate cancer.
The results of the CONDOR study show:
Among patients with recurrent prostate cancer, Pylarify showed a high correct localization and detection rate, including patients with low PSA values (median PSA of 0.8 ng/mL).
In these two clinical trials, Pylarify was well tolerated.
Pylarify PET imaging technology is expected to become a revolutionary diagnostic tool. Compared with traditional imaging detection, it allows doctors to detect suspected metastatic or recurrent prostate cancer more accurately at an early stage, and helps doctors formulate more precise treatment plans based on the condition of the disease to improve the benefit of prostate cancer patients.
(source:internet, reference only)
Disclaimer of medicaltrend.org